Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bradycardia Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Hypotension Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hospital das Forças Armadas

Brasília, Federal District, 70000000, Brazil

About this study

Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life.

Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Indication of anesthesia induction

Exclusion criteria

Protocol violation
Monitoring problems

Treatment and study plan

Remifentanil

Drug

bolus dose

Primary outcomes

hemodynamic stability during rapid sequence intubation

Time frame: from anesthesia induction up to 5 minutes

no bradycardia and no hypotension

Sponsors and collaborators

Lead sponsor

Brasilia University Hospital

Other

Registry information

Important dates

Study start: 2017
Primary completion: 2017
Study completion: 2017
First posted: Feb 27, 2017
Registry last updated: Sep 13, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed